SARS-CoV-2 vaccination and phase 1 cancer clinical trials
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
[...]a SARS-CoV-2 vaccine is likely to confer reduced protection in patients participating in phase 1 trials of experimental B cell-depleting antitumour drugs, such as monoclonal antibodies targeting CD10, CD19, or CD20, or CD19 chimeric antigen receptor T cells, given that such patients are unlikely to mount an optimal immune response.7 From exper...
Alternative Titles
Full title
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7906739
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7906739
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(21)00017-6
